Journal of Oral and Maxillofacial Surgery
Volume 65, Issue 7 , Pages 1321-1327 , July 2007

Hyperbaric Oxygen Treatment and Bisphosphonate-Induced Osteonecrosis of the Jaw: A Case Series

  • John J. Freiberger, MD, MPH

      Affiliations

    • Assistant Professor of Anesthesiology, Center for Hyperbaric Medicine and Environmental Physiology, Duke University Medical Center, Divers Alert Network, Durham, NC.
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Freiberger: Department of Anesthesiology, Center for Hyperbaric Medicine and Environmental Physiology, Box 3823, Duke University Medical Center, Durham, NC 27710
    • ,
  • Rebecca Padilla-Burgos, RN

      Affiliations

    • Staff Nurse, Center for Hyperbaric Medicine and Environmental Physiology, Duke University Medical Center, Durham, NC.
    • ,
  • Austin H. Chhoeu, DO

      Affiliations

    • Chief, Wound Care and Hyperbaric Medicine, Department of Surgery, Dwight D. Eisenhower Army Medical Center, Ft Gordon, GA.
    • ,
  • Kevin H. Kraft, RN

      Affiliations

    • Head Nurse, Center for Hyperbaric Medicine and Environmental Physiology, Duke University Medical Center, Durham, NC.
    • ,
  • Otto Boneta, MD, MPH

      Affiliations

    • Attending Physician, Hyperbaric Medicine Division, US Air Force School of Aerospace Medicine, Brooks City Base, San Antonio, TX.
    • ,
  • R.E. Moon, MD

      Affiliations

    • Professor of Anesthesiology and Associate Professor of Medicine, Center for Hyperbaric Medicine and Environmental Physiology, Duke University Medical Center, Divers Alert Network, Durham, NC.
    • ,
  • C.A. Piantadosi, MD

      Affiliations

    • Professor of Medicine, Center for Hyperbaric Medicine and Environmental Physiology, Duke University Medical Center, Durham, NC.

References 

  1. Marx RE. Pamidronate (Aredia)- and zoledronate (Zometa)-induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115
  2. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  3. Leite AF, Figueiredo PT, Melo NS, et al. Bisphosphonate-associated osteonecrosis of the jaws: Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:14
  4. Ashcroft J. Bisphosphonates and phossy-jaw: Breathing new life into an old problem. Lancet Oncol. 2006;7:447
  5. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol. 2006;24:945
  6. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions (Study of 20 cases). Oral Oncol. 2006;42:327
  7. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: A clinical report of 11 cases. Int J Oral Maxillofac Surg. 2006;35:588
  8. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99
  9. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep. 2003;1:45
  10. Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003;10:1165
  11. Ha H, Kwak HB, Lee SW, et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res. 2004;301:119
  12. Lee NK, Choi YG, Baik JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood. 2005;106:852
  13. Reddy SV. Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr. 2004;14:255
  14. Bai XC, Lu D, Liu AL, et al. Reactive oxygen species stimulates receptor activator of NF-κB ligand expression in osteoblast. J Biol Chem. 2005;280:17497
  15. Khosla S. Mini-review: The OPG/RANKL/RANK system. Endocrinology. 2001;142:5050
  16. Novartis Advisory Board. Report on osteonecosis of the jaw. London, UK: Novartis; 2006;
  17. Landesberg R, Wilson T, Grbic JT. Bisphosphonate-associated osteonecrosis of the jaw: Conclusions based on an analysis of case series. Dent Today. 2006;25:52
  18. Mignogna MD, Fedele S, Lo Russo L, et al. Case 2: Osteonecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol. 2006;24:1475
  19. Soileau KM. Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol. 2006;77:738
  20. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567
  21. Chiandussi S, Biasotto M, Dore F, et al. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol. 2006;35:236

PII: S0278-2391(07)00343-6

doi: 10.1016/j.joms.2007.03.019

Journal of Oral and Maxillofacial Surgery
Volume 65, Issue 7 , Pages 1321-1327 , July 2007

Article Tools

* Image Usage & Resolution